Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Enfuego Therapeutics Inc
Profile last edited on: 10/25/21      CAGE: 88ZM3      UEI: N4XYELPNM224

Business Identifier: RNA interference-(RNAi)-based and antisense oligo therapeutics
Year Founded
2019
First Award
2020
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

37 Linda Lee Circle
Pittsboro, NC 27312
   N/A
   N/A
   N/A
Location: Single
Congr. District: 04
County: Chatham

Public Profile

Enfuego Therapeutics Inc, spun out of University of North Carolina, develops RNA-interference drugs for cancer therapeutics. The company's primary focus is an investigational drug to shut down mutating versions of the GRAS gene, which is associated with many cancers including lung, pancreatic, and colon cancers. The company aims to develop a molecule drug to inhibit the function of mutated KRAS and find appropriate delivery methods for the treatment.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$224,995
Phase II Dollars
$0
Total Awarded
$224,995

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2020 1 NIH $224,995
Project Title: Development of EFTX-001 to Target Kras Mutations in Cancer
0 1 NIH $275,645
Project Title: Ligand-Directed KRAS G12V Mutant-Specific Therapeutics

Key People / Management

  Chad V Pecot -- Founder and CEO

  Lyla Stanland

Company News

Mar 16 2020
UNC Chapel-Hill Associate Professor Chad Pecot's startup company EnFuego Therapeutics creates RNA-interference drugs to silence cancer-related gene mutations
Dec 02 2019
NCBiotech awards grant to Pecot for studies of experimental RNAi therapy